Immunotherapy for Ovarian Cancer : Disappointing or Promising?
Ovarian cancer, one of the deadliest malignancies, lacks effective treatment, despite advancements in surgical techniques and chemotherapy. Thus, new therapeutic approaches are imperative to improving treatment outcomes. Immunotherapy, which has demonstrated considerable success in managing various cancers, has already found its place in clinical practice. This review aims to provide an overview of ovarian tumor immunotherapy, including its basics, key strategies, and clinical research data supporting its potential. In particular, this discussion highlights promising strategies such as checkpoint inhibitors, vaccines, and pericyte transfer, both individually and in combination. However, the advancement of new immunotherapies necessitates large controlled randomized trials, which will undoubtedly shape the future of ovarian cancer treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Molecular pharmaceutics - 21(2024), 2 vom: 05. Feb., Seite 454-466 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Deng, Mengqi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CAR-T therapy |
|---|
| Anmerkungen: |
Date Completed 06.02.2024 Date Revised 06.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1021/acs.molpharmaceut.3c00986 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367234920 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367234920 | ||
| 003 | DE-627 | ||
| 005 | 20240206232121.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240118s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acs.molpharmaceut.3c00986 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1282.xml |
| 035 | |a (DE-627)NLM367234920 | ||
| 035 | |a (NLM)38232985 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Deng, Mengqi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunotherapy for Ovarian Cancer |b Disappointing or Promising? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.02.2024 | ||
| 500 | |a Date Revised 06.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Ovarian cancer, one of the deadliest malignancies, lacks effective treatment, despite advancements in surgical techniques and chemotherapy. Thus, new therapeutic approaches are imperative to improving treatment outcomes. Immunotherapy, which has demonstrated considerable success in managing various cancers, has already found its place in clinical practice. This review aims to provide an overview of ovarian tumor immunotherapy, including its basics, key strategies, and clinical research data supporting its potential. In particular, this discussion highlights promising strategies such as checkpoint inhibitors, vaccines, and pericyte transfer, both individually and in combination. However, the advancement of new immunotherapies necessitates large controlled randomized trials, which will undoubtedly shape the future of ovarian cancer treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a CAR-T therapy | |
| 650 | 4 | |a checkpoint blockers | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a ovarian cancer | |
| 650 | 4 | |a vaccines | |
| 650 | 7 | |a Cancer Vaccines |2 NLM | |
| 700 | 1 | |a Tang, Fan |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Xiangyu |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Penglin |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Xuechao |e verfasserin |4 aut | |
| 700 | 1 | |a Hao, Menglin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yixiao |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Ruiye |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Qingqing |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yubo |e verfasserin |4 aut | |
| 700 | 1 | |a Miao, Jinwei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular pharmaceutics |d 2004 |g 21(2024), 2 vom: 05. Feb., Seite 454-466 |w (DE-627)NLM154556807 |x 1543-8392 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2024 |g number:2 |g day:05 |g month:02 |g pages:454-466 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acs.molpharmaceut.3c00986 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2024 |e 2 |b 05 |c 02 |h 454-466 | ||